Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ascendis Pharma A/S - American Depositary Shares (NQ:ASND)

225.00 -13.81 (-5.78%)
Streaming Delayed Price Updated: 2:06 PM EST, Jan 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Ascendis Pharma A/S - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND) Combines Minervini Trend Template with High Growth Momentum ↗
Via Chartmill
News headline image
Ascendis Pharma (NASDAQ:ASND) Passes Minervini's Trend Template and High Growth Momentum Scan ↗
Ascendis Pharma (ASND) meets Mark Minervini's strict criteria, showing a powerful technical uptrend paired with explosive revenue growth over 269%. 
Via Chartmill
News headline image
Why Dyne Therapeutics Stock Was Crushing it This Week ↗
The company has solid potential with its development of drugs targeting muscle disorders. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
European ADRs Navigate Choppy Waters: Pharma Sector Shows Resilience Amidst Broader Market Volatility
European American Depositary Receipts (ADRs) have recently experienced a period of significant fluctuation, reflecting a broader climate of market volatility that has ripple across global financial... 
Via MarketMinute
Topics Artificial Intelligence Economy Supply Chain
News headline image
Earnings Scheduled For November 12, 2025 ↗
 
Via Benzinga
News headline image
A Look Ahead: Ascendis Pharma's Earnings Forecast ↗
 
Via Benzinga
News headline image
How Do Investors Really Feel About Ascendis Pharma? ↗
 
Via Benzinga
News headline image
Ascendis (ASND) Q3 2025 Earnings Call Transcript ↗
Ascendis (ASND) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Ascendis Pharma Likely To Report Narrower Q3 Loss; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call ↗
 
Via Benzinga
News headline image
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years ↗
 
Via Benzinga
News headline image
Looking Into Ascendis Pharma AS's Recent Short Interest ↗
 
Via Benzinga
News headline image
Ascendis Pharma A/S - ADR (NASDAQ:ASND) Shows Strong Growth Momentum in Technical and Fundamental Analysis ↗
Ascendis Pharma (ASND) is a high-growth stock with strong technical uptrends and impressive fundamentals, including surging revenue and earnings momentum. 
Via Chartmill
News headline image
Earnings Scheduled For August 7, 2025 ↗
 
Via Benzinga
News headline image
Peering Into Ascendis Pharma's Recent Short Interest ↗
 
Via Benzinga
News headline image
Is Ascendis Pharma Gaining or Losing Market Support? ↗
 
Via Benzinga
News headline image
If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today ↗
 
Via Benzinga
News headline image
What Does the Market Think About Ascendis Pharma AS? ↗
Ascendis Pharma AS's (NYSE: ASND) short interest as a percent of float has fallen 14.63% since its last report. According to exchange reported data, there are now 2.29 million shares sold short, which... 
Via Benzinga
News headline image
$100 Invested In Ascendis Pharma 10 Years Ago Would Be Worth This Much Today ↗
Ascendis Pharma (NASDAQ: ASND) has outperformed the market over the past 10 years by 13.64% on an annualized basis producing an average annual return of 26.77%. Currently, Ascendis Pharma has a market... 
Via Benzinga
News headline image
PTC Therapeutics Could Challenge BioMarin For Metabolic Disorder Treatment ↗
BioMarin's Palynziq significantly lowered blood phenylalanine in teens with PKU, with nearly half reaching target levels in the Phase 3 study. 
Via Benzinga
News headline image
$100 Invested In Ascendis Pharma 10 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Here's How Much $100 Invested In Ascendis Pharma 10 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND) Combines Technical Strength and High-Growth Momentum ↗
Ascendis Pharma (ASND) excels in both technical & fundamental momentum, meeting Minervini's Trend Template criteria for high-growth stocks poised for potential outperformance. 
Via Chartmill
News headline image
If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today ↗
 
Via Benzinga
News headline image
Ascendis (ASND) Q2 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
What's Driving the Market Sentiment Around Ascendis Pharma? ↗
 
Via Benzinga
News headline image
What's Driving the Market Sentiment Around Ascendis Pharma? ↗
 
Via Benzinga
News headline image
$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Here's How Much $1000 Invested In Ascendis Pharma 10 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.